NEOGEN CORP (NEOG) Stock Fundamental Analysis
USA - NASDAQ:NEOG - US6404911066 - Common Stock
6.19 USD
+0.12 (+1.98%)
6.19 USD
0 (0%)
Overall NEOG gets a fundamental rating of 3 out of 10. We evaluated NEOG against 190 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NEOG was profitable.
NEOG had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
Each year in the past 5 years NEOG had a positive operating cash flow.
1.2 Ratios
NEOG has a Return On Assets (-30.88%) which is comparable to the rest of the industry.
NEOG has a Return On Equity (-49.23%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NEOG has a Gross Margin of 46.39%. This is comparable to the rest of the industry: NEOG outperforms 41.05% of its industry peers.
NEOG's Gross Margin has been stable in the last couple of years.
NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
The number of shares outstanding for NEOG has been increased compared to 5 years ago.
Compared to 1 year ago, NEOG has a worse debt to assets ratio.
2.2 Solvency
NEOG has an Altman-Z score of 0.80. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
NEOG has a Altman-Z score (0.80) which is in line with its industry peers.
A Debt/Equity ratio of 0.37 indicates that NEOG is not too dependend on debt financing.
NEOG has a Debt to Equity ratio (0.37) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.8 |
ROIC/WACCN/A
WACC7.61%
2.3 Liquidity
NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
NEOG has a Current ratio of 3.58. This is in the better half of the industry: NEOG outperforms 66.84% of its industry peers.
A Quick Ratio of 2.26 indicates that NEOG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.26, NEOG is in line with its industry, outperforming 58.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
The earnings per share for NEOG have been decreasing by -10.20% on average. This is quite bad
NEOG shows a decrease in Revenue. In the last year, the revenue decreased by -2.77%.
Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
NEOG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.40% yearly.
Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y-24.27%
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
EPS Next 5Y0.4%
Revenue Next Year-8.08%
Revenue Next 2Y-3.09%
Revenue Next 3Y-1.21%
Revenue Next 5Y0.6%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.63, which indicates a rather expensive current valuation of NEOG.
Based on the Price/Earnings ratio, NEOG is valued cheaper than 80.53% of the companies in the same industry.
NEOG is valuated rather cheaply when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 17.59, the valuation of NEOG can be described as rather expensive.
81.58% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.92. NEOG is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.63 | ||
| Fwd PE | 17.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 75.26% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.98 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.19
+0.12 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change-0.48%
Ins Owners0.42%
Ins Owner Change83.05%
Market Cap1.35B
Revenue(TTM)886.89M
Net Income(TTM)-1043097000
Analysts76.36
Price Target6.63 (7.11%)
Short Float %9.97%
Short Ratio3.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.85%
Min EPS beat(2)-34.64%
Max EPS beat(2)6.94%
EPS beat(4)2
Avg EPS beat(4)-6.75%
Min EPS beat(4)-34.64%
Max EPS beat(4)11.56%
EPS beat(8)2
Avg EPS beat(8)-12.49%
EPS beat(12)4
Avg EPS beat(12)45.16%
EPS beat(16)5
Avg EPS beat(16)24.16%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)0%
PT rev (3m)-23.53%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-41.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.94%
Revenue NQ rev (1m)-1.22%
Revenue NQ rev (3m)-9.75%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-6.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.63 | ||
| Fwd PE | 17.59 | ||
| P/S | 1.52 | ||
| P/FCF | N/A | ||
| P/OCF | 15.46 | ||
| P/B | 0.63 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.98 |
EPS(TTM)0.3
EY4.85%
EPS(NY)0.35
Fwd EY5.68%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.47%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.8 |
F-Score3
WACC7.61%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-24.27%
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
EPS Next 5Y0.4%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-8.08%
Revenue Next 2Y-3.09%
Revenue Next 3Y-1.21%
Revenue Next 5Y0.6%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.41%
EBIT Next 5Y19.96%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 3 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -24.27% in the next year.